bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies

Published on 31 Oct 2024 on Insider Monkey · via Yahoo Finance

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge...

Read the rest of the article

Start tracking your investments with Statfolio

Total Revenue: $10.6 million in Q3, down from $16.1 million in Q2. Projected Q4 Revenue: At least...

GuruFocus.com · via Yahoo Finance 14 Nov 2024

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge...

Insider Monkey · via Yahoo Finance 31 Oct 2024

bluebird bio BLUE registered revenues of $18.6 million in the first quarter, up from $2.4 million...

Zacks via Yahoo Finance 10 May 2024

bluebird bio, Inc. (NASDAQ:BLUE) Q1 2024 Earnings Call Transcript May 9, 2024 bluebird bio, Inc. ...

Insider Monkey via Yahoo Finance 10 May 2024

Bluebird bio Inc. (BLUE) has announced its first-quarter 2024 financial results, highlighting the...

Investing.com 10 May 2024

This development marks a major step in making the treatment accessible to patients with a history...

Investing.com 7 May 2024

Zoetis, Inc. ZTS is slated to report its first-quarter 2024 results on May 2, before market open....

Zacks via Yahoo Finance 25 Apr 2024

Walgreens Boots Alliance (WBA) expands specialty pharmacy services with dedicated unit for gene a...

Seeking Alpha 25 Apr 2024

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarte...

Insider Monkey via Yahoo Finance 24 Apr 2024

bluebird bio’s BLUE shares have lost 25.4% year to date compared with the industry’s decline of 7...

Zacks via Yahoo Finance 16 Apr 2024